Drug Trial Radar · NCT02164513
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Oct 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,355
Actual
Start
Jun 30, 2014
Primary completion
Jul 17, 2017
Study completion Jul 17, 2017
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 16, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Published studies which assessed the use of an 'open' triple therapy (use of Inhaled Corticosteroid \[ICS\]/ Long-acting Muscarinic Receptor Antagonists \[LAMA\])/ Long Acting Beta-Agonist \[LABA\] delivered via multiple inhalers) in moderate-severe COPD patients, reported improvements in lung function, Health Related Quality of Life (HRQoL), hospitalization rates and rescue medication use, compared to dual therapy (ICS/LABA) or LAMA alone. These studies have also shown similar safety profile with dual or monotherapy doses for periods of up to one year. Given the clinical experience with FF, UMEC and VI, and that the associated risks with these compounds are anticipated from their known pharmacology, the potential benefit of a new therapy option in patients with moderate to severe COPD supports the further development of the closed triple combination (delivered via one inhaler). In the current study subjects meeting all inclusion/exclusion criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety follow-up period. Eligible subjects will be randomized to one of the following double-blind treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100 mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate (FF)Drug
FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
vilanterol (VI)Drug
VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
umeclidinium bromide (UMEC)Drug
UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VITime frame: Up to Week 52
Locations
998 sites in 37 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Athens, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Florence, Alabama
GSK Investigational Site
Jasper, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Muscle Shoals, Alabama
GSK Investigational Site
Sheffield, Alabama
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Flagstaff, Arizona
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Peoria, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Arcadia, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Chula Vista, California
GSK Investigational Site
Encinitas, California
GSK Investigational Site
Escondido, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Mission Hills, California
GSK Investigational Site
Modesto, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Palo Alto, California
GSK Investigational Site
Reseda, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
Rolling Hills Estates, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Santa Ana, California
GSK Investigational Site
Santa Monica, California
GSK Investigational Site
Torrance, California
GSK Investigational Site
Tustin, California
GSK Investigational Site
Upland, California
Showing 40 of 998 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.